However, anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF) or the vascular endothelial growth factor receptor (VEGFR) rarely result in durable responses and have had a limited effect on improving the overall survival of patients with lung cancer [14]. This evidence concerns the gene VEGFA and lung cancer.